Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Common Equity (2016 - 2026)

Mimedx's Common Equity history spans 17 years, with the latest figure at $242.9 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 19.81% to $242.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $242.9 million, a 19.81% increase, with the full-year FY2025 number at $256.5 million, up 32.85% from a year prior.
  • Common Equity hit $242.9 million in Q1 2026 for Mimedx, down from $256.5 million in the prior quarter.
  • Over the last five years, Common Equity for MDXG hit a ceiling of $256.5 million in Q4 2025 and a floor of -$19.5 million in Q3 2022.
  • Historically, Common Equity has averaged $112.4 million across 5 years, with a median of $155.7 million in 2024.
  • Biggest five-year swings in Common Equity: crashed 22036.59% in 2022 and later skyrocketed 13509.62% in 2024.
  • Tracing MDXG's Common Equity over 5 years: stood at -$18.0 million in 2022, then skyrocketed by 893.4% to $142.7 million in 2023, then soared by 35.31% to $193.1 million in 2024, then skyrocketed by 32.85% to $256.5 million in 2025, then decreased by 5.31% to $242.9 million in 2026.
  • Business Quant data shows Common Equity for MDXG at $242.9 million in Q1 2026, $256.5 million in Q4 2025, and $238.9 million in Q3 2025.